|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miyake M, Fujimoto K, Anai S, Ohnishi S,
Nakai Y, Inoue T, Matsumura Y, Tomioka A, Ikeda T, Tanaka N, et al:
Clinical significance of heme oxygenase-1 expression in
non-muscle-invasive bladder cancer. Urol Int. 85:355–363. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nepple KG and O'Donnell MA: The optimal
management of T1 high-grade bladder cancer. Can Urol Assoc J.
3(Suppl 4): S188–S192. 2009.PubMed/NCBI
|
|
4
|
Hendricksen K and Witjes JA: Current
strategies for first and second line intravesical therapy for
nonmuscle invasive bladder cancer. Curr Opin Urol. 17:352–357.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kikuchi E, Fujimoto H, Mizutani Y, Okajima
E, Koga H, Hinotsu S, Shinohara N, Oya M and Miki T; Cancer
Registration Committee of the Japanese Urological Association:
Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive
bladder cancer from the data on registered bladder cancer patients
in japan: 1999–2001 report from the Japanese Urological
Association. Int J Urol. 16:279–286. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Peyromaure M, Guerin F, Amsellem-Ouazana
D, Saighi D, Debre B and Zerbib M: Intravesical bacillus
Calmette-Guerin therapy for stage T1 grade 3 transitional cell
carcinoma of the bladder: Recurrence, progression and survival in a
study of 57 patients. J Urol. 169:2110–2112. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shahin O, Thalmann GN, Rentsch C,
Mazzucchelli L and Studer UE: A retrospective analysis of 153
patients treated with or without intravesical bacillus
Calmette-Guerin for primary stage T1 grade 3 bladder cancer:
Recurrence, progression and survival. J Urol. 169:96–100;
discussion 100. 2003. View Article : Google Scholar
|
|
8
|
Shelley MD, Jones G, Cleves A, Wilt TJ,
Mason MD and Kynaston HG: Intravesical gemcitabine therapy for
non-muscle invasive bladder cancer (NMIBC): A systematic review.
BJU Int. 109:496–505. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cambier S, Sylvester RJ, Collette L,
Gontero P, Brausi MA, van Andel G, Kirkels WJ, Silva FC,
Oosterlinck W, Prescott S, et al: EORTC nomograms and risk groups
for predicting recurrence, progression, and disease-specific and
overall survival in non-muscle-invasive stage Ta-T1 urothelial
bladder cancer patients treated with 1–3 years of maintenance
Bacillus Calmette-Guérin. Eur Urol. 69:60–69. 2016. View Article : Google Scholar
|
|
10
|
Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi
H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, et
al: Mutation of the mouse klotho gene leads to a syndrome
resembling ageing. Nature. 390:45–51. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kurosu H, Yamamoto M, Clark JD, Pastor JV,
Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M,
Kawaguchi H, et al: Suppression of aging in mice by the hormone
Klotho. Science. 309:1829–1833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kuro-o M: Klotho. Pflugers Arch.
459:333–343. 2010. View Article : Google Scholar
|
|
13
|
Urakawa I, Yamazaki Y, Shimada T, Iijima
K, Hasegawa H, Okawa K, Fujita T, Fukumoto S and Yamashita T:
Klotho converts canonical FGF receptor into a specific receptor for
FGF23. Nature. 444:770–774. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kuro-o M: Klotho and aging. Biochim
Biophys Acta. 1790:1049–1058. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamamoto M, Clark JD, Pastor JV, Gurnani
P, Nandi A, Kurosu H, Miyoshi M, Ogawa Y, Castrillon DH, Rosenblatt
KP, et al: Regulation of oxidative stress by the anti-aging hormone
klotho. J Biol Chem. 280:38029–38034. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ito S, Kinoshita S, Shiraishi N, Nakagawa
S, Sekine S, Fujimori T and Nabeshima YI: Molecular cloning and
expression analyses of mouse betaklotho, which encodes a novel
Klotho family protein. Mech Dev. 98:115–119. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu MC and Moe OW: Klotho as a potential
biomarker and therapy for acute kidney injury. Nat Rev Nephrol.
8:423–429. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kurosu H, Choi M, Ogawa Y, Dickson AS,
Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA and
Kuro-o M: Tissue-specific expression of betaKlotho and fibroblast
growth factor (FGF) receptor isoforms determines metabolic activity
of FGF19 and FGF21. J Biol Chem. 282:26687–26695. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goetz R, Beenken A, Ibrahimi OA, Kalinina
J, Olsen SK, Eliseenkova AV, Xu C, Neubert TA, Zhang F, Linhardt
RJ, et al: Molecular insights into the klotho-dependent, endocrine
mode of action of fibroblast growth factor 19 subfamily members.
Mol Cell Biol. 27:3417–3428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wolf I, Levanon-Cohen S, Bose S, Ligumsky
H, Sredni B, Kanety H, Kuro-o M, Karlan B, Kaufman B, Koeffler HP,
et al: Klotho: A tumor suppressor and a modulator of the IGF-1 and
FGF pathways in human breast cancer. Oncogene. 27:7094–7105. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie B, Zhou J, Yuan L, Ren F, Liu DC, Li Q
and Shu G: Epigenetic silencing of Klotho expression correlates
with poor prognosis of human hepatocellular carcinoma. Hum Pathol.
44:795–801. 2013. View Article : Google Scholar
|
|
22
|
Chen B, Wang X, Zhao W and Wu J: Klotho
inhibits growth and promotes apoptosis in human lung cancer cell
line A549. J Exp Clin Cancer Res. 29:992010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu Y, Xu L, Zhang J, Xu W, Liu Y, Yin H,
Lv T, An H, Liu L, He H, et al: Klotho suppresses tumor progression
via inhibiting PI3K/Akt/GSK3β/Snail signaling in renal cell
carcinoma. Cancer Sci. 104:663–671. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Doi S, Zou Y, Togao O, Pastor JV, John GB,
Wang L, Shiizaki K, Gotschall R, Schiavi S, Yorioka N, et al:
Klotho inhibits transforming growth factor-beta1 (TGF-beta1)
signaling and suppresses renal fibrosis and cancer metastasis in
mice. J Biol Chem. 286:8655–8665. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Poh W, Wong W, Ong H, Aung MO, Lim SG,
Chua BT and Ho HK: Klotho-beta overexpression as a novel target for
suppressing proliferation and fibroblast growth factor receptor-4
signaling in hepatocellular carcinoma. Mol Cancer. 11:142012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ye X, Guo Y, Zhang Q, Chen W, Hua X, Liu
W, Yang Y and Chen G: βKlotho suppresses tumor growth in
hepatocellular carcinoma by regulating Akt/GSK-3β/cyclin D1
signaling pathway. PLoS One. 8:e556152013. View Article : Google Scholar
|
|
27
|
Feng S, Dakhova O, Creighton CJ and
Ittmann M: Endocrine fibroblast growth factor FGF19 promotes
prostate cancer progression. Cancer Res. 73:2551–2562. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim HS, Kim M, Jeong CW, Kwak C, Kim HH
and Ku JH: Presence of lymphovascular invasion in urothelial
bladder cancer specimens after transurethral resections correlates
with risk of upstaging and survival: A systematic review and
meta-analysis. Urol Oncol. 32:1191–1199. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cho KS, Seo HK, Joung JY, Park WS, Ro JY,
Han KS, Chung J and Lee KH: Lymphovascular invasion in
transurethral resection specimens as predictor of progression and
metastasis in patients with newly diagnosed T1 bladder urothelial
cancer. J Urol. 182:2625–2630. 2009. View Article : Google Scholar : PubMed/NCBI
|
